M. El-Serafi

Oxaliplatin/5‐fluorouracil‐based adjuvant chemotherapy as a standard of care for colon cancer in clinical practice: Outcomes of the ACCElox registry

J. Ji, A. Buzaid, J. Zalcberg, 2015, Asia-Pacific journal of clinical oncology.

The prognostic value of c‐Kit, K‐ras codon 12, and p53 codon 72 mutations in Egyptian patients with stage II colorectal cancer

Mahmoud M. Kamel, A. Bahnassy, A. Zekri, 2010, Cancer.

Genetic-Environmental Interaction in Acute Lymphatic Leukemia

Y. Al-Tonbary, H. El-Tahan, M. Hafez, 1985 .

Genetic Susceptibility in Hodgkin’s Lymphoma

Y. Al-Tonbary, H. El-Tahan, M. Hafez, 1985 .

Cyclin A and Cyclin D1 as Significant Prognostic Markers in Egyptian Patients with Colorectal Carcinoma

A. Bahnassy, A. Zekri, Kasr El-Aini, 2002 .

Cyclin A and cyclin D1 as significant prognostic markers in colorectal cancer patients

A. Bahnassy, A. Zekri, A. El-shehaby, 2004, BMC gastroenterology.

Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1).

R. Labianca, L. Collette, A. Carrato, 2008, European journal of cancer.

Neoadjuvant chemotherapy plus conventional radiotherapy or accelerated hyperfractionation in stage III and IV nasopharyngeal carcinoma--a phase II study.

V. Mosseri, Y. Khafaga, E. Ibrahim, 2001, Acta oncologica.